Thank you for your interest in QIAGEN microbiome workflow solutions.
A sales representative will contact you soon with your tailored discount offer.
Over the past two decades, there has been a growing shift away from using the century-old tuberculin skin test to using a modern blood test with interferon gamma release assays (IGRAs). Today, IGRAs are the preferred test in national guidelines for most routine and high-risk TB screening. However, familiarity of these newer assays has lagged behind the rapid policy changes and growing body of scientific evidence. Since the launch of QuantiFERON-TB Gold Plus (QFT-Plus), there have been new scientific advancements demonstrating the value of CD8 T cell response that provides health care providers with a more comprehensive picture of a patient’s immune response to TB.
Join Dr. Masae Kawamura, Senior Director of Scientific and Medical Affairs for TB diagnostics, QIAGEN, who will provide an overview of testing for TB infection and the scientific evidence behind the growing domestic and global use of IGRAs. Dr. Kawamura will discuss new literature on QFT-Plus and how it performs in high-risk populations. She will also provide the latest case study scenarios for practical application with QFT-Plus, QIAGEN’s fourth-generation IGRA.
QuantiFERON-TB Gold Plus (QFT-Plus) is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus Package Inserts as well as up-to- date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.